NEW YORK (GenomeWeb News) – MolecularMD has submitted a Premarket Approval application with the US Food and Drug Administration for a companion diagnostic test to leukemia drug ponatinib.

The Portland, Ore.-based firm said after the close of the market Monday that it had filed for clearance of its BCR-ABL T315I Mutation Test, which detects the T315I mutation in BCR-ABL RNA transcripts in blood using Sanger sequencing technology. It said the test can identify patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia who have the mutation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.